Epigenetic Therapies for Cancer

This review summarises approved agents and their clinical activity, describes therapies in development, and delineates challenges in the field of epigenetics. It covers the DNMT inhibitors, KMT Inhibitors and HDAC inhibitors.

New England Journal of Medicine